TY - JOUR
T1 - Tau accumulates differently in four subtypes of Alzheimer's disease
AU - Yoshizaki, Takahito
AU - Minatani, Shinobu
AU - Namba, Hiroto
AU - Takeda, Akitoshi
AU - Kawabe, Joji
AU - Mizuta, Hideko
AU - Wada, Yasuhiro
AU - Mawatari, Aya
AU - Watanabe, Yasuyoshi
AU - Shimada, Hitoshi
AU - Higuchi, Makoto
AU - Itoh, Yoshiaki
N1 - Publisher Copyright:
© 2023 Japanese Society of Neurology and John Wiley & Sons Australia, Ltd.
PY - 2023/7
Y1 - 2023/7
N2 - Background: Heterogeneity in Alzheimer's disease (AD) has been reported on the basis of clinical, neuropathological, and neuroimaging data. However, most of the indices, including cerebral atrophy evaluated using magnetic resonance imaging and amyloid β (Aβ) accumulation detected using positron emission tomography (PET), lack sensitivity, and specificity for categorization. Aim: Herein, we used a novel PET ligand for tau to estimate the differential distribution of tau in the subtypes of AD. Methods: Patients with posterior cortical atrophy (PCA; n = 3), frontal variant of AD (FAD; n = 1), logopenic variant primary progressive aphasia (LPPA; n = 2), typical AD (TAD; n = 6), and healthy controls (HC; n = 12) were studied. Aβ and tau accumulation were evaluated using [11C]PiB and [11C]PBB3, respectively. Results: Amyloid β accumulation was confirmed in all PCA, FAD, LPPA, and TAD cases. Tau accumulation was dominantly high in the occipital lobes in the PCA, strikingly high in the frontal lobes in the FAD, and moderately high in the angular gyrus of the dominant hemisphere in the LPPA. Tau accumulation in TAD cases was significantly higher than age-dependent tau accumulation in HC in these subtype-specific regions as well as in AD signature regions. Glucose utilization was reversely correlated with PBB3 accumulation in the subtype-specific regions. Conclusions: Tau accumulates differently in the four subtypes of AD, suggesting that tau pathology may be closely associated with unique clinical features.
AB - Background: Heterogeneity in Alzheimer's disease (AD) has been reported on the basis of clinical, neuropathological, and neuroimaging data. However, most of the indices, including cerebral atrophy evaluated using magnetic resonance imaging and amyloid β (Aβ) accumulation detected using positron emission tomography (PET), lack sensitivity, and specificity for categorization. Aim: Herein, we used a novel PET ligand for tau to estimate the differential distribution of tau in the subtypes of AD. Methods: Patients with posterior cortical atrophy (PCA; n = 3), frontal variant of AD (FAD; n = 1), logopenic variant primary progressive aphasia (LPPA; n = 2), typical AD (TAD; n = 6), and healthy controls (HC; n = 12) were studied. Aβ and tau accumulation were evaluated using [11C]PiB and [11C]PBB3, respectively. Results: Amyloid β accumulation was confirmed in all PCA, FAD, LPPA, and TAD cases. Tau accumulation was dominantly high in the occipital lobes in the PCA, strikingly high in the frontal lobes in the FAD, and moderately high in the angular gyrus of the dominant hemisphere in the LPPA. Tau accumulation in TAD cases was significantly higher than age-dependent tau accumulation in HC in these subtype-specific regions as well as in AD signature regions. Glucose utilization was reversely correlated with PBB3 accumulation in the subtype-specific regions. Conclusions: Tau accumulates differently in the four subtypes of AD, suggesting that tau pathology may be closely associated with unique clinical features.
UR - http://www.scopus.com/inward/record.url?scp=85153067404&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85153067404&partnerID=8YFLogxK
U2 - 10.1111/ncn3.12715
DO - 10.1111/ncn3.12715
M3 - Article
AN - SCOPUS:85153067404
SN - 2049-4173
VL - 11
SP - 231
EP - 238
JO - Neurology and Clinical Neuroscience
JF - Neurology and Clinical Neuroscience
IS - 4
ER -